瑞士诺华的地拉罗司治疗效果好吗

It is an orally active chelating agent that is highly selective for ferric iron. It is a trifurcated ligand that can bind high-affinity iron ions in a ratio of 2:1. This product promotes the excretion of iron, mainly in the feces. This product has low affinity for copper and zinc and will not cause persistently low serum concentrations of these metals. It is suitable for the treatment of adults and children over 2 years old with chronic siderosis (transfusion-induced siderosis) caused by blood transfusion.

According to a retrospective study in Italy, 42.7% of patients achieved a hematological response and reduced the need for blood transfusions after receiving DFO or deferasirox chelation therapy. There may be a dynamic, bidirectional regulatory mechanism between erythropoiesis and iron overload. On the one hand, ineffective erythropoiesis can lead to increased intestinal iron absorption through reduced hepcidin secretion by the liver. On the other hand, chelation treatment of iron overload can improve erythropoiesis, increase hemoglobin levels, and reduce clinical blood transfusions.

Currently, the one most favored by patients is the one produced by Novartis in Switzerland. Novartis is a pharmaceutical and biotechnology multinational company headquartered in Basel, Switzerland. Its core businesses are in various patent medicines, consumer healthcare, generic medicines, eye care and animal health. According to Medical Companion Travel, the specification of Deferasirox from Novartis Switzerland is 400mg*30 tablets, but the price is only 420$, which is more suitable for patients for long-term use. Since the exchange rate is not static, the price will also fluctuate. For details, please consult Medical Companion Travel.

Recommended related hot articles: /newsDetail/94102.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.